Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical diagnostic company OraSure Technologies (NASDAQ: OSUR ) jumped 11% today after getting two glowing reports from analysts.
So what: Nicholas Jansen at Raymond James upgraded the stock to outperform and set a price target of $8 per share because he thinks sales of hepatitis C and HIV tests will pick up as health insurance coverage expands. Janney Capital Markets analyst Spencer Nam maintained a buy rating and a $10 price target on hope that sales will pick up as early as the fourth quarter.
Now what: Stocks will often pop on upgrades like this and then drift lower as the early euphoria wears off. Keep in mind that even analysts are expecting OraSure to report a loss both this year and next, so there's a lot of progress to be made. Instead of buying on an analyst upgrade, I'd look at what the company reports and says about the future after the third quarter because fundamental progress is what will drive the stock long-term. If sales begin to pick up that will tell me a lot more than an analyst rating.
A health care opportunity coming quick
Obamacare is rewriting the rules for the health care industry, and in the process of doing so, it's creating massive opportunities for investors to get ridiculously rich. How? By investing in a handful of specific health care stocks. In this free report, our analysts walk you through these opportunities and the companies that are positioned to exploit them. The informational edge contained in it is invaluable, but can only be exploited profitably while the rest of the market remains in the dark. To access this free report instantly, simply click here now.
Interested in more info on OraSure Technologies? Add it to your watchlist by clicking here.